GLP-3RT Research Hub — Advanced Metabolic Pathway Studies
GLP-3RT is Ares Research's advanced metabolic research compound, studied alongside the broader incretin literature. This hub aggregates reference material on the GLP-1, GLP-1/GIP and triagonist pathways that frame contemporary metabolic research.
What this hub covers
- GLP-1 and GLP-1/GIP receptor signalling literature
- Comparisons to semaglutide and tirzepatide research models
- Body weight, glycaemic and lipid endpoints in published studies
- Reconstitution and handling for laboratory research
GLP-3RT research articles
All research →Semaglutide Half-Life & Pharmacokinetics — Research Guide (2026)
Research-only pharmacokinetic profile of Semaglutide: serum half-life, Tmax, route comparisons, clearance and bioavailability — curated from published preclinical and clinical PK literature.
Read article →Tirzepatide Half-Life & Pharmacokinetics — Research Guide (2026)
Research-only pharmacokinetic profile of Tirzepatide: serum half-life, Tmax, route comparisons, clearance and bioavailability — curated from published preclinical and clinical PK literature.
Read article →Tirzepatide vs Cagrilintide — Research Comparison (2026)
Tirzepatide vs cagrilintide compared: dual GIP/GLP-1 incretin vs long-acting amylin analog, mechanism, dosing and stacking research.
Read article →AOD-9604 vs Semaglutide — Research Comparison (2026)
AOD-9604 vs semaglutide for body-composition research: lipolysis-targeted GH fragment vs GLP-1 receptor agonist.
Read article →Semaglutide Research Overview
Semaglutide is a long-acting GLP-1 receptor agonist — a fatty acid–conjugated glucagon-like peptide-1 analogue with a one-week plasma half-life — approved as Ozempic (diabetes) and Wegovy (obesity), and now the subject of the most comprehensive cardiometabolic and emerging neurological research programme of any peptide-class compound in modern pharmacology.
Read article →Tirzepatide Research Overview
Tirzepatide is the world's first dual GIP/GLP-1 receptor co-agonist — a 39-amino acid synthetic peptide (Mounjaro; Zepbound) achieving unprecedented weight loss of up to 22.5% in clinical trials, and redefining the ceiling of pharmacological obesity treatment through simultaneous activation of two complementary incretin hormone pathways.
Read article →Semaglutide Benefits and Side Effects: A Research Guide
Published benefits, side effects, and cardiovascular-outcomes evidence for semaglutide — the most extensively characterised GLP-1 receptor agonist in the modern incretin literature.
Read article →Tirzepatide Benefits and Side Effects: A Research Guide
Published benefits, side effects, and semaglutide/Retatrutide comparisons for tirzepatide — the GLP-1/GIP dual agonist that established GIP-receptor co-agonism as a productive metabolic axis.
Read article →Retatrutide Benefits and Side Effects: A Research Guide
Published benefits, side effects, and tirzepatide/semaglutide comparisons for Retatrutide — the investigational GLP-1/GIP/glucagon triple agonist with the largest body-weight reductions reported for any non-surgical incretin pharmacotherapy.
Read article →Retatrutide vs Semaglutide — Research Comparison
Side-by-side research comparison of retatrutide (GLP-1/GIP/glucagon triple agonist) and semaglutide (GLP-1 mono-agonist) — mechanism, pharmacokinetics, and metabolic-research literature.
Read article →Retatrutide vs Tirzepatide — Research Comparison
Triple agonist (retatrutide) vs dual agonist (tirzepatide) — side-by-side research comparison of receptor targets, pharmacokinetics, and published metabolic data.
Read article →Semaglutide vs Tirzepatide: Research Comparison
Side-by-side comparison of semaglutide and tirzepatide receptor activity, half-life, and metabolic research findings.
Read article →Semaglutide Dosing & Protocols — Research Reference
Reference compilation of semaglutide titration schedules, reconstitution, dosing tiers, and metabolic endpoint markers.
Read article →Tirzepatide Dosing & Protocols — Research Reference
Reference compilation of tirzepatide titration schedules, reconstitution, dosing tiers, and metabolic endpoints from the published research literature.
Read article →Retatrutide Dosing & Protocols — Research Reference
Reference compilation of retatrutide titration, dosing tiers, and triple-agonist endpoint markers from published research.
Read article →Semaglutide Reconstitution & Storage — Research Guide
Reference guide for semaglutide reconstitution ratios, bacteriostatic water volumes, concentration tables, refrigerated stability, and titration handling practice.
Read article →Tirzepatide Reconstitution & Storage — Research Guide
Reference guide for tirzepatide reconstitution, BAC water volumes, dual-agonist concentration tables, refrigerated stability, and titration handling practice.
Read article →Retatrutide Reconstitution & Storage — Research Guide
Reference guide for retatrutide reconstitution ratios, BAC water volumes, triple-agonist concentration tables, refrigerated stability, and titration practice.
Read article →Semaglutide Side Effects — Laboratory Research Reference
Documented adverse-event profile of semaglutide across STEP and SUSTAIN trial programs: GI tolerability, gallbladder, pancreatic, thyroid C-cell and injection-site signals — referenced for research context only.
Read article →Tirzepatide Side Effects — Laboratory Research Reference
Adverse-event profile of the dual GIP/GLP-1 agonist tirzepatide across the SURMOUNT and SURPASS programs: GI events, pancreatic and gallbladder signals, hypoglycemia risk in combination, and injection-site reactivity.
Read article →Retatrutide Side Effects — Laboratory Research Reference
Reported tolerability of the triple GIP/GLP-1/glucagon agonist retatrutide across published Phase 2 data: dose-related GI adverse events, heart-rate effects, and titration considerations referenced for research context.
Read article →Semaglutide Mechanism of Action — Receptor, Signalling & Pharmacokinetics
Receptor pharmacology of the long-acting GLP-1 receptor agonist semaglutide: binding affinity, downstream Gαs/cAMP/PKA signalling, gastric emptying, central appetite circuits and albumin-anchored PK.
Read article →Tirzepatide Mechanism of Action — Dual GIP/GLP-1 Receptor Pharmacology
Receptor pharmacology of the dual GIP/GLP-1 receptor agonist tirzepatide: imbalanced agonism, downstream signalling differences from semaglutide, and the metabolic consequences of GIP arm activation.
Read article →GLP-3RT research FAQ
- Where does GLP-3RT sit in the metabolic research landscape?
- GLP-3RT (Ares Apex-3) is studied as an advanced metabolic research compound, evaluated against the wider incretin literature that includes GLP-1 mono-agonists (semaglutide) and GLP-1/GIP dual agonists (tirzepatide). The hub's featured articles provide the published-literature backdrop for those comparisons.
- How does it compare to semaglutide in published research?
- Semaglutide is a well-characterised GLP-1 receptor agonist with extensive clinical-trial data on glycaemic and body-weight endpoints. The semaglutide research overview summarises that dataset, which forms the baseline for evaluating newer metabolic research compounds.
- What is the relevance of tirzepatide to GLP-3RT research?
- Tirzepatide is a dual GLP-1/GIP receptor agonist whose published trials documented additive metabolic effects compared with GLP-1 mono-agonism. It is a key reference point for any multi-receptor metabolic research programme.
- Is GLP-3RT intended for human use?
- No. Like every compound in the Ares Research catalogue, GLP-3RT is supplied strictly for laboratory research use only and is not for human or veterinary consumption.
All content on this hub is provided strictly for laboratory research purposes. Compounds listed are not for human or veterinary consumption. See our research-use disclosure for full terms.